LMAT · XBRL financial data

Lemaitre Vascular financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LMAT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	129,366	154,424	161,651	193,484	219,863	249,602
Cost of goods and services sold	44,748	53,042	56,755	66,435	68,962	71,063
Gross profit	84,618	101,382	104,896	127,049	150,901	178,539
Research and development	10,099	11,801	13,294	16,966	15,650	14,139
General and administrative	22,501	25,501	28,745	31,832	36,258	42,024
Total operating expenses	55,830	64,957	78,067	90,337	98,645	110,627
Operating income (loss)	28,788	36,425	26,829	36,712	52,256	67,912
Interest income	207	197	986	3,077	4,949	13,094
Interest expense	1,310	2,219	0	0	205	5,184
Other income (expense)	(329)	(116)	(325)	(314)	(125)	(638)
Income tax expense (benefit)	6,136	7,380	6,854	9,370	12,837	17,450
Net income (loss)	21,220	26,907	20,636	30,105	44,038	57,734
Earnings per share, basic USD per share	1.05	1.27	0.94	1.36	1.96	2.55
Earnings per share, diluted USD per share	1.04	1.25	0.93	1.34	1.93	2.52
Weighted average shares, basic thousands of shares	20,246	21,157	21,975	22,217	22,452	22,638
Weighted average shares, diluted thousands of shares	20,479	21,475	22,171	22,423	22,779	22,929

Fiscal years (LMAT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	26,764	13,855	19,134	24,269	25,610	28,244
Marketable securities	214	56,104	63,557	80,805	274,112	330,876
Accounts receivable	19,552	19,631	22,040	25,064	30,063	33,610
Prepaid and other current assets	2,618	4,189	6,731	6,380	7,480	5,080
Total current assets	94,263	139,883	161,733	194,598	402,192	468,232
Property and equipment, net	15,036	17,059	17,901	21,754	24,800	26,997
Right-of-use asset	16,066	15,071	15,634	18,027	16,768	15,762
Goodwill	65,945	65,945	65,945	65,945	65,945	65,945
Total assets	252,810	292,802	310,476	346,778	551,817	615,690
Accounts payable	2,394	2,340	2,903	3,734	1,761	3,646
Accrued liabilities	17,525	16,332	19,967	23,650	24,732	29,411
Total current liabilities	25,145	21,813	25,329	29,879	30,607	36,323
Lease liability, non-current	14,791	14,067	14,710	16,624	15,232	14,003
Total liabilities	80,238	38,651	42,275	48,878	214,527	222,174
Retained earnings	70,554	88,125	97,773	115,430	145,090	184,715
Total stockholders' equity	172,572	254,151	268,201	297,900	337,290	393,516
Total liabilities and equity	252,810	292,802	310,476	346,778	551,817	615,690
Common shares outstanding (cover page) thousands of shares	20,527	21,929	22,097	22,337	22,559	22,778

Fiscal years (LMAT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	21,220	26,907	20,636	30,105	44,038	57,734
Stock-based compensation	3,022	3,479	4,173	5,319	6,568	7,826
Depreciation and amortization	8,395	11,070	9,433	9,515	9,670	10,418
Net cash from operating activities	34,800	35,102	25,378	36,751	44,124	81,251
Net cash from investing activities	(52,891)	(61,076)	(10,371)	(24,715)	(200,120)	(64,941)
Proceeds from issuing common stock	5,971	63,241	3,466	6,170	6,440	—
Share repurchases	570	802	642	853	1,719	1,821
Dividends paid	7,695	9,336	10,988	12,448	14,378	18,109
Net cash from financing activities	32,155	13,702	(9,234)	(7,131)	158,102	(14,540)
Net change in cash	14,978	(12,909)	5,279	5,135	1,341	2,634

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lemaitre Vascular	26,625	not reported	15,965*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Ufp Technologies	9,045	173,964	15,612*	7.7M	—	Q2 FY26 10-QJun 30, 2026
AtriCure	167,786	153,604	22,192*	50.9M	—	Q2 FY26 10-QJun 30, 2026
Heartflow	34,362	64,082	(8,577)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026
Enovis	12,563	582,782	75,032*	57.7M	—	Q2 FY26 10-QJul 3, 2026
Artivion	77,316	125,757	(1,266)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
Alphatec Holdings	79,936	221,172	18,856*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	62,818	254,560	(34,630)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Haemonetics	223,384	339,380	52,323	45.5M	—	Q1 FY27 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.